LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Search

Biogen Inc

Abierto

SectorSanidad

137.84 0.31

Resumen

Variación precio

24h

Actual

Mínimo

135.28

Máximo

137.65

Métricas clave

By Trading Economics

Ingresos

394M

635M

Ventas

215M

2.6B

P/B

Media del Sector

13.46

35.69

BPA

3.02

Margen de beneficios

23.995

Empleados

7,605

EBITDA

457M

1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+21.72% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.9B

21B

Apertura anterior

137.53

Cierre anterior

137.84

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

131 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Biogen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 sept 2025, 18:25 UTC

Principales Movimientos del Mercado

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 sept 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 sept 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 sept 2025, 23:45 UTC

Charlas de Mercado

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 sept 2025, 23:34 UTC

Charlas de Mercado

Oil Falls on Likely Technical Correction -- Market Talk

27 sept 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept 2025, 20:54 UTC

Ganancias

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

26 sept 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 19:54 UTC

Charlas de Mercado

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept 2025, 19:53 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 19:40 UTC

Ganancias

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept 2025, 19:17 UTC

Charlas de Mercado

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept 2025, 19:15 UTC

Charlas de Mercado

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept 2025, 18:50 UTC

Charlas de Mercado
Ganancias

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept 2025, 18:36 UTC

Charlas de Mercado

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept 2025, 17:54 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept 2025, 16:56 UTC

Charlas de Mercado
Ganancias

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept 2025, 16:41 UTC

Charlas de Mercado
Ganancias

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept 2025, 16:26 UTC

Ganancias

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Biogen Inc previsión

Precio Objetivo

By TipRanks

21.72% repunte

Estimación a 12 Meses

Media 167.2 USD  21.72%

Máximo 224 USD

Mínimo 118 USD

De acuerdo con 26 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

26 ratings

12

Comprar

14

Mantener

0

Vender

Puntuación técnica

By Trading Central

118.15 / 121.17Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

131 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat